Motor neurons and central nervous system cells

Motor neurons and central nervous system (CNS) cells are the fundamental units of the nervous system, with motor neurons specifically responsible for transmitting signals from the brain and spinal cord to muscle fibers to initiate movement (NIH, 2023). This entry does not represent a single molecular target but rather a complex cellular environment containing various therapeutic targets such as ion channels, neurotransmitter receptors, and specific gene sequences. Dysfunction or degeneration of these cells is the hallmark of several devastating conditions, including Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), and Multiple Sclerosis (MS) (StatPearls, 2023). Therapeutic interventions aimed at these cells often involve small molecules like Riluzole, which modulates glutamate neurotransmission, or advanced gene therapies like Nusinersen and Onasemnogene abeparvovec that address genetic deficiencies (FDA, 2023). A significant challenge in targeting these cells is the blood-brain barrier, which limits the delivery of many systemic drugs, often necessitating specialized delivery methods like intrathecal injection. Monitoring the health of these cells in clinical trials frequently involves measuring biomarkers of axonal injury, such as neurofilament light chain (NfL) (PubMed, 2022). Overall, while the cells themselves are not a discrete target, they serve as the critical site of action for a wide range of neurotherapeutic agents.

Other names

Motor neuronsCentral nervous system cellsCNS neuronsLower motor neuronsUpper motor neuronsNerve cells

Drugs targeting these cells typically act by modulating specific molecular pathways within them, such as glutamate signaling, survival motor neuron (SMN) protein production, or superoxide dismutase 1 (SOD1) mRNA degradation (FDA, 2023).